(P034) Proton Therapy (PT) Large-Volume Re-Irradiation for Recurrent Glioma: Overall Survival (OS) and Toxicity Outcomes

OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

Large-volume PT re-irradiation for recurrent glioma is safe and associated with promising OS outcomes, particularly in the setting of bevacizumab-refractory tumors.

Brijal M. Desai, MD, Russell C. Rockne, PhD, Irene B. Helenowski, MS, PhD, Jeffrey J. Raizer, MD, Nina Paleologos, MD, Ryan Merrell, MD, Sean Grimm, MD, Syed Azeem, MD, William F. Hartsell, MD, Patrick Sweeney, MD, Kristin R. Swanson, PhD, Vinai Gondi, MD; Northwestern University Feinberg School of Medicine; Rush University Medical Center; Northshore University Health Systems; Cadence Brain Tumor Center; CDH Proton Center

BACKGROUND: The therapeutic benefit of targeting T2/fluid-attenuated inversion recovery (FLAIR) in addition to contrast-enhancing (CE) tumor during re-irradiation for recurrent glioma is attenuated by augmented toxicity. Given its steep dose falloff and narrow penumbrae, proton therapy (PT) minimizes the volume of brain parenchyma outside of the target volume, potentially permitting safer delivery of large-volume re-irradiation.

METHODS: From February 2011 to April 2014, a total of 21 consecutive adult patients with recurrent glioma who were treated with PT re-irradiation at a single institution were retrospectively analyzed. Planning target volume (PTV) included T2/FLAIR and CE abnormalities. The covariates that were assessed were age, gender, Karnofsky performance status (KPS) at time of PT, number of pre-PT recurrences, grade at initial diagnosis, interval between PT and prior radiotherapy (PRT), PT dose, PT PTV, bevacizumab failure, concurrent use of temozolomide and/or bevacizumab, and post-PT radiation necrosis. Overall survival (OS) time from PT start was estimated with Kaplan-Meier analysis; comparisons used the log-rank statistic. Multivariate analysis used the Cox proportional hazards model.

RESULTS: Median age was 43 years, and median KPS was 90. The median number of salvage treatments was 2 (range: 1–9). Median interval between PRT and PT was 32.8 months (range: 6.9–162.9 mo). A total of 13 patients (62%) were bevacizumab-refractory. Median PT dose was 50.51 Cobalt Gray Equivalent (CGE), and median PTV was 224.2 cc. Five patients (24%) remain alive. Median OS was 10.5 months overall, 6.3 months among bevacizumab-refractory patients, and 12.4 months among bevacizumab-naive patients. Prior bevacizumab failure (hazard ratio [HR] = 3.77; P = .02), lower KPS score (HR = 1.03; P = .047), and decreased interval between PRT and PT (≤ 40 mo; HR = 3.46; P = .04) were prognostic of inferior OS. On multivariate analysis, decreased interval between PRT and PT (P = .02) remained prognostic of inferior OS, but lower KPS and prior bevacizumab failure trended to significance (P = .07). One patient had grade 3 necrosis in the setting of PT re-irradiation for progressive brainstem glioma. One patient had grade 2 necrosis, and another had grade 2 stroke. No other grade ≥ 3 toxicities were observed.

CONCLUSION: Large-volume PT re-irradiation for recurrent glioma is safe and associated with promising OS outcomes, particularly in the setting of bevacizumab-refractory tumors.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Recent Videos
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Related Content